A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer

Davelaar, Elvira M.; Lande, Jonas van de; Mensdorff‐Pouilly, Silvia von; Blankenstein, Marinus A.; Verheijen, René H.M.; Kenemans, P.

doi:10.1159/000132566

Cited by 26 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our test data is in agreement with the results of other researchers regarding the diagnostic usefulness of antigen SCC in this malignancy [26][27][28]. Moreover, its prognostic significance, both for recurrence-free and overall survival, has been confirmed by other researchers in the early stages of cervical cancer [29].…”

Section: Discussionsupporting

confidence: 92%

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Ławicki

Będkowska

Gacuta-Szumarska

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:In this study, we compared plasma levels and the diagnostic utility of hematopoietic growth factors (HGFs) with SCC-Ag in cervical cancer patients in relation to control groups and cervical intraepithelial neoplasia (CIN) patients and healthy subjects. Pretreatment plasma levels of HGFs (SCF, GM-CSF, G-CSF and M-CSF) were determined by the use of immunoenzyme assay (ELISA), and SCC-Ag by chemiluminescent microparticle immunoassay (CMIA). Significantly different concentrations of GM-CSF, G-CSF and M-CSF were observed in the group of patients with cervical cancer and CIN compared to the healthy controls. Significant differences in plasma levels of GM-CSF and M-CSF between cervical cancer and benign lesions patients were also found. The HGFs and SCC-Ag diagnostic specificities received high values. The diagnostic sensitivity and the predictive value of a positive and negative test result were higher for M-CSF than for antigen SCC in the cancer group. The M-CSF area under the ROC curve (AUC) was the largest from hematopoietic cytokines and SCC-Ag. These results suggest the potential utility of M-CSF as a good candidate for a marker of cervical cancer as well as benign lesions of this organ (CIN).

show abstract

Section: Discussionsupporting

confidence: 92%

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Ławicki

Będkowska

Gacuta-Szumarska

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…21 However, the clinical relevance of these tumor-associated antigens is still debated. 22 Because to our knowledge there is no validated tumor marker, 5 there is an urgent need to identify new biomarkers for the early detection and management of patients with cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

Garg

Kanojia

Salhan

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…Currently, the most widely used clinical screening system for cervical lesions in women in the gynecology clinic is HPV testing in combination with TCT examination. CYFRA21-1 is a common serum tumor marker of squamous cell carcinoma which has a certain significance in auxiliary diagnosis of cervix lesions [7][8][9][10]. In this study, during the statistical analysis of gynecology clinic outpatients, several observations were made.…”

Section: Discussionmentioning

confidence: 99%

The application of CYFRA21-1 in cervical lesions screening in high-risk human papillomavirus infected women

Feng

Yang²,

Yan-chun³

2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: To investigate the role of cytokeratin-19 fragment (CYFRA21-1) in cervical lesions screening in high-risk human papillomavirus (HR-HPV) infected women. Material and methods:The study was a retrospective study. First, the results of CYFRA21-1, cytology (TCT), and HR-HPV examinations of 1039 outpatients from gynecology department in Tumor Hospital Affiliated to Xinjiang Medical University were collected. Then, the data was analyzed using a series of statistical methods. Results:There was a correlation between CYFRA21-1 levels and HPV-DNA load in HR-HPV infected women (r s = 0.711, p = 0.015). CYFRA21-1 levels and positive rate increased along with deepening of cervical cell lesions. In HR-HPV infected women, there was a statistically significant difference (t = 6.022, p < 0.001) in CYFRA21-1 levels between the group with cytological lesions (4.87 ± 1.58 ng/mL) and the group with normal cytology (2.52 ± 0.96 ng/mL). Positive rates of CY-FRA21-1 in the two groups were 62.06% and 7.83%, respectively, and also exhibited statistically significant differences (χ 2 = 74.624, p < 0.001). When diagnosing cytological lesions via CYFRA21-1 in HR-HPV infected women, sensitivity was 62.07%, specificity was 92.17%, positive predictive value was 88.89%，negative predictive value was 70.67%. Compared to CYFRA21-1 negative women, cytological lesions were detected 19.273 times more often in CYFRA21-1 positive women. Conclusion:CYFRA21-1 could provide a reference idea for further diagnosis of women who are infected with HR-HPV but whose cytology is normal.

show abstract

A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer

Cited by 26 publications

References 29 publications

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

The application of CYFRA21-1 in cervical lesions screening in high-risk human papillomavirus infected women

Contact Info

Product

Resources

About